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progressionThe importance of the microenvironment for cancer develop-
ment and progression is now widely recognised, but it is worth
reminding ourselves that this is a relatively young area of research.
Anyone searching PubMed today using the terms “cancer, micro-
environment” will ﬁnd over 22,000 scientiﬁc publications, with
around 3000 new contributions in both 2014 and 2015. However,
going back 10 years to 2004 there were only 364 papers published
ﬁtting these terms, hence keen researchers would have the capa-
city to read them all. Changing the search terms to “cancer, mi-
croenvironment, bone”, results in 3400 papers with around 420
new contributions per year for 2014 and 2015, compared with 93
papers a decade earlier. Inclusion of the word “therapy” limits the
number of hits further, but in all cases the trend is towards ever
increasing numbers of annual scientiﬁc publications that include
studies of the microenvironment, indicating an active research
area in rapid growth.
The renewed interest in the microenvironment in cancer may
in part come as a result of the realisation that the human genome
project (completed 2003) did not deliver as much insight into
cancer development as was hoped. Subsequent efforts to sequence
cancer cell genomes and identify driver mutations were published
from 2006 onwards, with the data on new cancer types regularly
emerging, most recently in breast cancer [1]. However, it was clear
that the translation of this wealth of new data into knowledge and
increased understanding of cancer biology, ultimately identifying
new therapeutic targets, was going to take time, and that new
gene-based cancer therapies were not just round the corner [2].
The concerted effort of the Cancer Genome Atlas (TGCA) program
(started in 2006) has yielded a wealth of information relating to
cancer-subtypes and identiﬁed numerous mutations, but proces-
sing and interpreting its 20 petabytes of data, including 10 million
mutations, is a mammoth task [3].
As the complexities of the cancer cell genome and its regulation
became evident, scientists also started to consider how different
cell types work together, and Hannahan and Weinberg predicted
this to be of great importance in their original “Hallmarks of Can-
cer” paper published in 2000 [4]. In this they stated: “Looking
forward in time, we believe that important new inroads will come
from regarding tumours as complex tissues in which mutant cancer
cells have conscripted and subverted normal cell types to serve as
active collaborators in their neoplastic agenda. The interactions be-
tween the genetically altered malignant cells and these supporting
co-conspirators will prove critical to understanding cancer patho-
genesis and to the development of novel, effective therapies.” This
statement has turned out to be astonishingly accurate, reﬂectingx.doi.org/10.1016/j.jbo.2016.05.004
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standing, and ultimately successfully treating, cancer, depends on
unravelling how a multitude of cell types co-operate. How the
components of the microenvironment contribute to tumour de-
velopment was subsequently mapped on to the hallmarks of
cancer in the 2012 paper from Hannahan and Coussens “Acces-
sories to the Crime: Functions of Cells Recruited to the Tumour Mi-
croenvironment”, which describes the contribution of a large
number of both cellular and molecular components to tumour
progression [5]. At the same time as huge efforts were made to
characterise individual cancer cells, there was increasing realisa-
tion that tumours are heterogeneous, both in terms of the tumour
cells [6] but also in their stromal component [7], and that the
presence of different clones underpins the development of re-
sistance to therapy. This heterogeneity introduces further layers of
complexity in our quest to understand cancer, and highlights that
analysis of individual components of a tumour and characterisa-
tion of single cells may not be fruitful.
For researchers with an interest in bone metastasis, the role of
the microenvironment has always been an integral part of their
thinking. As described by Rob Coleman in this issue (see page 90),
bone-targeted therapies were shown to be effective in advanced
disease in the early 1980s, initiating research into the connection
between bone and tumour growth. This ultimately generated the
hypothesis of the vicious cycle proposed by Mundy and colleagues,
where tumour-bone interactions result in accelerated tumour
growth and associated cancer-induced bone disease [8]. Initially,
the focus of bone metastasis research was the osteoclast and its
key role in cancer-induced bone disease. However, it soon became
clear that even highly effective inhibition of bone resorption was
insufﬁcient to prevent tumour progression in bone, suggesting
that other cell types and numerous molecular/cellular drivers were
involved. As described by Le Pape and colleagues in this issue (see
page 93), the role of the osteoclast in cancer-induced bone disease
is now well characterised. However, the role of the osteoclast in
the early stages of tumour cell colonization of bone is less clear,
with recent studies using multi-photon microscopy to demon-
strate that zoledronic acid treatment does not inhibit tumour cell
homing to bone in mice [9]. The osteoclast may therefore have a
role in the subsequent steps of stimulating the growth of dis-
seminated tumour cells to form colonies.
With improving models and technologies, including cell la-
beling and imaging, researchers are increasingly able to study the
early stages of bone metastasis, prior to development of overt
bone disease. This has generated new insights into the cellular andCC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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introducing a host of new players with the potential to enhance
tumour cell homing, survival and subsequent colonization of bone
that in turn may represent novel therapeutic targets. For many of
these we are only just starting to unravel their interactions with
tumour cells. This special issue of JBO includes descriptions of a
large number of different elements of the microenvironment af-
fecting bone metastasis, from the early stages (preparing the
niche) through tumour cell homing, survival and colonization to
progression and advanced disease. At every step there is co-op-
eration between cancer cells and their surroundings, highlighting
that agents targeting these interactions may present novel ther-
apeutic opportunities. The challenges are to hit the right cell types
at the right locations at the right stage of the process, as the scope
for off-target effects is considerable. For example, we want to
eliminate tumour-associated vessels without damaging the nor-
mal vasculature. Similarly, it may be desirable to develop agents
that will eliminate tumour promoting, but not tumour suppres-
sing, macrophage subtypes.1. Preparing the soil
If we consider microenvironmental inﬂuences at each stage of
the metastatic process in order, the ﬁrst is the role of systemic
factors generated by the primary tumour in preparing the future
site of secondary colonization, the pre-metastatic niche [10].
Ubellacker and McAllister (see page 96) describe how primary
tumour-derived factors interact with numerous cell populations in
the bone marrow, mobilizing haematopoietic and mesenchymal
cells into the circulation and in some cases recruitment into per-
ipheral tumours. Despite intensive research, they point out that
systemic instigation of bone metastases (in humans) remain to be
demonstrated.
One such systemic factor, LOX, has recently been shown to
increase bone metastasis in murine models. Gartland et al (see
page 100) describe how the secretion of the enzyme LOX by tu-
mour cells initiates alterations in the bone extracellular matrix and
facilitates the development of pre-metastatic bone lesions. These
lesions comprise areas of bone where the physical, biochemical
and biomechanical properties of the extracellular matrix compo-
nents are altered, creating an environment suitable for subsequent
tumour cell colonization. Targeting of secreted proteins should
therefore be considered as future therapeutic options in the con-
text of bone metastasis.
Amongst the newest systemic factors to be described in rela-
tion to bone metastasis are miRNAs, and as described by Zoni and
van der Pluijm (see page 104) a number of these have been sug-
gested to be involved in different stages of the process, including
in preparation of the pre-metastatic niche. With their capacity to
modify multiple cell types (including osteoblasts and osteoclasts),
these molecules may contribute to the cancer-induced alterations
of the bone microenvironment that underpins subsequent meta-
static progression. miRNAs are likely produced by all cell types and
can be both pro- and anti-tumourigenic, hence their precise role in
cancer progression and potential as therapeutic targets require
further research.2. Homing to bone
Megakaryocytes and platelets have also been shown to modify
different steps of bone metastasis in model systems, covered by
Leblanc and Peyruchaud in this issue (see page 109). Platelets are
pro-metastatic, supporting survival of circulating tumour cells and
their extravasation at secondary sites. The platelet-derived factorlysophosphatidic acid (LPA) is shown to enhance bone metastasis,
and anti-platelet treatment combined with aspirin reduced bone
metastasis in mice [11]. Platelet producing megakaryocytes also
generate a number of factors that regulates bone turnover (like
BMPs), and animals deﬁcient in transcription factor required for
megakaryocyte maturation have low platelet counts but highly
increased bone mass due to elevated osteoblast numbers [12].
Recent technological advances have facilitated detailed charc-
terisation of the bone microvasculature, as described by Kusumbe
(see page 112). As tumour cells reach bone through the circulation,
the role of the vessels are clearly important in bone metastasis and
the perivascular niche suggested to be a supportive environment
for disseminated tumour cells. The identiﬁcation of particular ca-
pillary types (Hþ capillaries) that are surrounded by osteopro-
genitor cells in the metaphysis of mouse long bones illustrate the
close coupling between osteogenesis and angiogenesis, which also
may have implications for disseminated tumour cells. Of particular
interest is the report by Ghajar et al. [13] that dormant cancer cells
are located close to stable vasculature, whereas vascular re-
modeling was associated with proliferating tumour cells.
Hematopoietic stem cell in tumour cell homing to bone has
been established in models of prostate cancer, and as described by
Taichman and colleagues (see page 117), chemo-attractants and
attachment factors generated in the HSC niche may also act to
facilitate the homing and survival of prostate cancer cells to these
niches. The concept that cancer cells reside in the HSC niche and
are able to respond to the same signals as govern the dormancy/
proliferation status of HSC opens up new therapeutic avenues.
Whether different cancer types (most notably breast cancer) also
locate to HSC niches remain to be established.
As covered by Morris and Edwards (see page 121), an adipo-
cyte-rich bone marrow microenvironment may contribute to
creating a permissive niche for cancer cells, as well as provide the
energy that help fuel their progression into overt tumours. Adi-
pocytes also produce a range of pro-tumourigenic chemokines,
and targeting of these adipokines may contribute to reduced tu-
mour growth.
Whether cells of the osteoblast lineage are key components of
the metastatic niche has been the subject of some debate, as de-
scribed by Ottewell (see page 124). Their contribution to tumour
cell homing, survival, maintenance of dormancy remains to be
established although a number of reports suggest that tumour
cells locate to the endosteal niche in models of breast and prostate
cancer. How alterations in bone turnover rates, decreasing or in-
creasing osteoblast activity, affects disseminated tumour cells is
unclear.3. Established colonies and tumour progression
Once tumour cells have successfully colonized bone, they start
to recruit other cell types to support their expansion. Prajapati and
Lambert highlight that compared to the role of cancer-associated
ﬁbroblasts (CAFs) in primary tumours, their involvement in bone
metastasis remains poorly understood (see page 128). This is in
part due to their heterogeneity and lack of speciﬁc markers to
identify subtypes with different organ preference. As CAFs are
abundant in tumours and a source of numerous pro-tumourigenic
growth factors and cytokines, it is highly likely that they are also a
part of the bone metastatic microenvironment. Their relative ge-
netic stability (compared to tumour cells) suggests that they are
unlikely to develop resistance to therapy and may therefore be
suitable targets for intervention.
Bone is highly innervated and bone homeostasis is regulated
through the release of norepinephrine by sympathetic nerves.
Although the involvement of the nervous system has been
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disease, Elefteriou (see page 132) describes how there could also
be involvement at earlier stages of metastatic spread. Chronic
immobilization stress has been shown to increase the number of
bone metastasis in an in vivo model of bone metastasis, as well as
increase the severity of the associated lytic lesions. Whether this is
relevant for human disease remains an intriguing possibility,
opening novel avenues for therapeutic intervention.
Although established as key players in the development of
metastases in general, it has been more difﬁcult to pin down the
precise role of macrophages in bone metastasis, as described by
Sousa and Maatta (see page 135). In part this is due to the het-
erogeneity of and plasticity of these cells, but also the lack of
macrophage-speciﬁc agents that can be used to elucidate their
functions in vivo. The ideal scenario is to develop therapeutic
strategies to prevent the formation of pro-tumorigenic macro-
phages and at the same time stimulate the tumour-suppressing
populations, suppressing secondary tumour formation.
Many of the components described above contribute to tumour
response to anti-cancer agents, including the vessels, osteoclasts
etc. Less is known about how the endocrine system, in particular
hormones, modify bone metastasis and therapeutic response. The
article by Wilson (see page 139), describes the potential role of
female reproductive hormones in breast cancer bone metastasis.
As recent clinical trials have shown a difference between pre- and
post-menopausal women in terms of survival beneﬁt from ad-
juvant bisphosphonates [14], understanding how the hormonal
status of the microenvironment affects disseminated tumour cells
is the subject of intensive research efforts.
In addition to the cellular and molecular components described
above, physical/chemical properties of the bone microenviron-
ment are also likely to inﬂuence development and progression of
metastasis. Alterations in the level of extracellular calcium (see
article by Brenner, page 143) can affect tumour cells through cal-
cium sensing receptors (CaSR) or calcium binding proteins. A
number of studies have manipulated the expression of CaSR in
tumour cells and found that this reduces Ca-stimulated migration/
invasion. Speciﬁc CaSRs have been shown to be associated with
increased ability to form bone metastasis in vivo. These and other
data suggest that a reduction in extracellular calcium levels caused
by anti-resorptive therapy may contribute to reduced tumour
growth through reduced signaling by CaSRs.
As highlighted by many of the authors contributing to this is-
sue, the complexity of the bone microenvironment, and the dy-
namic nature of its interaction with cancer cells, presents both
challenges and opportunities in the context of therapeutic tar-
geting. However, the overall consensus is that continued research
efforts in this area will result in new agents and treatmentstrategies that will improve the outcome for patients with skeletal
metastases.References
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